治疗强度非减量肝素的管理:关于关键点的叙述性综述。

TH open : companion journal to thrombosis and haemostasis Pub Date : 2024-10-17 eCollection Date: 2024-07-01 DOI:10.1055/a-2359-0987
Isabelle Gouin-Thibault, Alexandre Mansour, Michael Hardy, Pierre Guéret, Emmanuel de Maistre, Virginie Siguret, Adam Cuker, François Mullier, Thomas Lecompte
{"title":"治疗强度非减量肝素的管理:关于关键点的叙述性综述。","authors":"Isabelle Gouin-Thibault, Alexandre Mansour, Michael Hardy, Pierre Guéret, Emmanuel de Maistre, Virginie Siguret, Adam Cuker, François Mullier, Thomas Lecompte","doi":"10.1055/a-2359-0987","DOIUrl":null,"url":null,"abstract":"<p><p>Nowadays, unfractionated heparin (UFH) use is limited to selected patient groups at high risk of both bleeding and thrombosis (patients in cardiac surgery, in intensive care unit, and patients with severe renal impairment), rendering its management extremely challenging, with many unresolved questions despite decades of use. In this narrative review, we revisit the fundamental concepts of therapeutic anticoagulation with UFH and address five key points, summarizing controversies underlying the use of UFH and discussing the few recent advances in the field: (1) laboratory tests for UFH monitoring have significant limitations; (2) therapeutic ranges are not well grounded; (3) the actual influence of antithrombin levels on UFH's anticoagulant activity is not well established; (4) the concept of UFH resistance lacks supporting data; (5) scarce data are available on UFH use beyond acute venous thromboembolism. We therefore identified key issues to be appropriately addressed in future clinical research: (1) while anti-Xa assays are often considered as the preferred option, we call for a vigorous action to improve understanding of the differences between types of anti-Xa assays and to solve the issue of the usefulness of added dextran; (2) therapeutic ranges for UFH, which were defined decades ago using reagents no longer available, have not been properly validated and need to be confirmed or reestablished; (3) UFH dose adjustment nomograms require full validation.</p>","PeriodicalId":94220,"journal":{"name":"TH open : companion journal to thrombosis and haemostasis","volume":"8 3","pages":"e297-e307"},"PeriodicalIF":0.0000,"publicationDate":"2024-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11486528/pdf/","citationCount":"0","resultStr":"{\"title\":\"Management of Therapeutic-intensity Unfractionated Heparin: A Narrative Review on Critical Points.\",\"authors\":\"Isabelle Gouin-Thibault, Alexandre Mansour, Michael Hardy, Pierre Guéret, Emmanuel de Maistre, Virginie Siguret, Adam Cuker, François Mullier, Thomas Lecompte\",\"doi\":\"10.1055/a-2359-0987\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Nowadays, unfractionated heparin (UFH) use is limited to selected patient groups at high risk of both bleeding and thrombosis (patients in cardiac surgery, in intensive care unit, and patients with severe renal impairment), rendering its management extremely challenging, with many unresolved questions despite decades of use. In this narrative review, we revisit the fundamental concepts of therapeutic anticoagulation with UFH and address five key points, summarizing controversies underlying the use of UFH and discussing the few recent advances in the field: (1) laboratory tests for UFH monitoring have significant limitations; (2) therapeutic ranges are not well grounded; (3) the actual influence of antithrombin levels on UFH's anticoagulant activity is not well established; (4) the concept of UFH resistance lacks supporting data; (5) scarce data are available on UFH use beyond acute venous thromboembolism. We therefore identified key issues to be appropriately addressed in future clinical research: (1) while anti-Xa assays are often considered as the preferred option, we call for a vigorous action to improve understanding of the differences between types of anti-Xa assays and to solve the issue of the usefulness of added dextran; (2) therapeutic ranges for UFH, which were defined decades ago using reagents no longer available, have not been properly validated and need to be confirmed or reestablished; (3) UFH dose adjustment nomograms require full validation.</p>\",\"PeriodicalId\":94220,\"journal\":{\"name\":\"TH open : companion journal to thrombosis and haemostasis\",\"volume\":\"8 3\",\"pages\":\"e297-e307\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-10-17\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11486528/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"TH open : companion journal to thrombosis and haemostasis\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1055/a-2359-0987\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/7/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"TH open : companion journal to thrombosis and haemostasis","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1055/a-2359-0987","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/7/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

如今,非分数肝素(UFH)的使用仅限于特定的出血和血栓形成高风险患者群体(心脏手术患者、重症监护室患者和严重肾功能损害患者),这使得其管理极具挑战性,尽管已使用数十年,但仍有许多问题悬而未决。在这篇叙述性综述中,我们重温了 UFH 治疗性抗凝的基本概念,并讨论了五个关键点,总结了 UFH 使用中存在的争议,并讨论了该领域近期取得的一些进展:(1) 用于监测 UFH 的实验室检测有很大的局限性;(2) 治疗范围没有很好的依据;(3) 抗凝血酶水平对 UFH 抗凝活性的实际影响尚未得到很好的证实;(4) UFH 耐药性的概念缺乏支持数据;(5) 有关急性静脉血栓栓塞症以外 UFH 使用的数据很少。因此,我们确定了在未来临床研究中需要妥善解决的关键问题:(1) 虽然抗 Xa 检测通常被认为是首选方案,但我们呼吁采取积极行动,进一步了解不同类型抗 Xa 检测之间的差异,并解决添加右旋糖酐是否有用的问题;(2) 几十年前使用不再可用的试剂确定的 UFH 治疗范围尚未得到适当验证,需要确认或重新确定;(3) UFH 剂量调整提名图需要全面验证。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Management of Therapeutic-intensity Unfractionated Heparin: A Narrative Review on Critical Points.

Nowadays, unfractionated heparin (UFH) use is limited to selected patient groups at high risk of both bleeding and thrombosis (patients in cardiac surgery, in intensive care unit, and patients with severe renal impairment), rendering its management extremely challenging, with many unresolved questions despite decades of use. In this narrative review, we revisit the fundamental concepts of therapeutic anticoagulation with UFH and address five key points, summarizing controversies underlying the use of UFH and discussing the few recent advances in the field: (1) laboratory tests for UFH monitoring have significant limitations; (2) therapeutic ranges are not well grounded; (3) the actual influence of antithrombin levels on UFH's anticoagulant activity is not well established; (4) the concept of UFH resistance lacks supporting data; (5) scarce data are available on UFH use beyond acute venous thromboembolism. We therefore identified key issues to be appropriately addressed in future clinical research: (1) while anti-Xa assays are often considered as the preferred option, we call for a vigorous action to improve understanding of the differences between types of anti-Xa assays and to solve the issue of the usefulness of added dextran; (2) therapeutic ranges for UFH, which were defined decades ago using reagents no longer available, have not been properly validated and need to be confirmed or reestablished; (3) UFH dose adjustment nomograms require full validation.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
审稿时长
12 weeks
期刊最新文献
Management of Therapeutic-intensity Unfractionated Heparin: A Narrative Review on Critical Points. Impact of Clinical Decision Support with Mandatory versus Voluntary Venous Thromboembolism Risk Assessment in Hospitalized Patients. An Intestinal Microbiome Intervention Affects Biochemical Disease Activity in Patients with Antiphospholipid Syndrome. Corrigendum: Bleeding Risk Prediction in Patients Treated with Antithrombotic Drugs According to the Anatomic Site of Bleeding, Indication for Treatment, and Time Since Treatment Initiation. Establishing Expectancy Values for Fibrin Monomer in Uncomplicated Pregnancy.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1